Form 4: Director David Lamond Receives Quince Therapeutics Options

Quince Therapeutics director David Lamond was granted 2,700 stock options as part of a standard equity compensation package.

Summary

• Director David Lamond acquired 2,700 stock options in Quince Therapeutics, Inc. (QNCX).
• The options have an exercise price of $0.947 per share.
• The grant date for these options is June 11, 2026.
• The options are set to expire on June 11, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified; this is a routine compensatory equity grant.

Risks

• The value of the options is subject to the future market performance of QNCX common stock.

Future Outlook

The options vest 100% on the one-year anniversary of the grant date, June 11, 2027.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure board members maintain a vested interest in company performance.

Comparison to Industry Standards

• The grant of stock options to non-executive directors is consistent with standard compensation practices for small-cap biotechnology firms.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity incentive grant.

Next Steps

• Vesting of the 2,700 stock options on June 11, 2027.

Key Dates

Keywords

Quince Therapeutics, QNCX, Form 4, Insider Trading, Stock Options, Director Compensation